Keros Therapeutics, Inc.
KROS
$14.36
$0.1951.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 91,657.69% | 2,250.99% | 8,037.50% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 91,657.69% | 2,250.99% | 8,037.50% | -- | -- |
| Cost of Revenue | 45.82% | -- | -75.35% | -86.17% | -92.85% |
| Gross Profit | 3,046.23% | 2,250.99% | 75.88% | 86.42% | 93.09% |
| SG&A Expenses | 9.58% | 16.99% | 19.41% | 25.84% | 27.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.16% | 26.04% | 31.67% | 34.81% | 38.80% |
| Operating Income | 94.26% | -24.06% | -31.26% | -34.62% | -38.62% |
| Income Before Tax | 109.08% | -22.26% | -27.45% | -32.81% | -37.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 102.63% | -22.46% | -27.45% | -32.81% | -37.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 102.63% | -22.46% | -27.45% | -32.81% | -37.84% |
| EBIT | 94.26% | -24.06% | -31.26% | -34.62% | -38.62% |
| EBITDA | 94.95% | -23.93% | -31.11% | -34.46% | -38.68% |
| EPS Basic | 97.21% | 3.52% | -5.26% | -13.01% | -16.74% |
| Normalized Basic EPS | 102.17% | 3.66% | -5.27% | -13.01% | -16.74% |
| EPS Diluted | 75.38% | 1.55% | -5.45% | -42.37% | -46.99% |
| Normalized Diluted EPS | 101.32% | 3.66% | -5.27% | -13.01% | -16.74% |
| Average Basic Shares Outstanding | 23.59% | 27.13% | 21.34% | 18.71% | 18.79% |
| Average Diluted Shares Outstanding | 23.96% | 27.13% | 21.34% | 18.71% | 18.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |